MicroGenDX continues to expand its growth and expertise in molecular diagnostics by acquiring sampling innovator Captigen along with Captigen’s extensive inventory of flatswabs. The Captigen flatswab is a cross-platform precision microbial sampling device designed for optimized culture yield, RT-PCR yield, and next-generation sequencing (NGS). The Captigen flatswab is intended to improve the absorption and release of the specimen, while ensuring ease-of-use in a sterile field. Other advantages include:
- Validated for SARS-CoV-2 recovery via RT-PCR
- Validated for 36-hour dry specimen hold at room temperature
- Offers an easy-to-use ejector tip that minimizes cross-contamination
“We’ve been using the Captigen flatswab for over a year now as a supplement to gauze in our testing,” says Rick Martin, CEO of MicroGenDX. “We’ve found that, with proper sampling technique, this flatswab has advantages for reliable DNA extraction. With this acquisition we not only obtained an excellent sampling tool, but have also secured a large inventory of flatswabs during uncertain times that have plagued our industry with supply chain disruptions.”
Founded in 2008, MicroGenDX has become the industry leader in rapid turnaround and affordability for comprehensive Next-Generation Sequencing (NGS) and qPCR testing for clinical diagnostics. MicroGenDX is CLIA-licensed and CAP-accredited, and has been the trusted research partner for the CDC, U.S. Army, and NASA. MicroGenDX has published over 70 clinical studies and is the most experienced molecular microbial diagnostic laboratory with more than 1.5 million tests processed.